Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 12/20 | 1.00 |
| ▸ | CACNA2D1 | P54289 | 7/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.65 |
| ▸ | MLNR | O43193 | 1/20 | 0.65 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | DRD2 | P14416 | 1/20 | 0.65 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.65 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
| ▸ | MC4R | P32245 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3967638 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2CACNA2D1SLC6A3MLNR | |
| Hydrochloric Acid SCHEMBL4413256 | 0.99 | SLC6A4 (0.98) | SLC6A4SLC6A2CACNA2D1SLC6A3MLNR | |
| Phosphoric Acid SCHEMBL3624 | 0.93 | SLC6A4 (0.87) | SLC6A4SLC6A2CACNA2D1SLC6A3MLNR | |
| Oxalic Acid SCHEMBL3448 | 0.93 | SLC6A4 (0.87) | SLC6A4SLC6A2CACNA2D1SLC6A3MLNR | |
| SCHEMBL20292549 | 0.87 | CACNA2D1 (1.00) | SLC6A4SLC6A2CACNA2D1 | |
| SCHEMBL20292572 | 0.87 | CACNA2D1 (1.00) | SLC6A4SLC6A2CACNA2D1 | |
| SCHEMBL20292510 | 0.87 | CACNA2D1 (1.00) | SLC6A4SLC6A2CACNA2D1 | |
| SCHEMBL20292511 | 0.87 | CACNA2D1 (1.00) | SLC6A4SLC6A2CACNA2D1 | |
| SCHEMBL20292593 | 0.87 | CACNA2D1 (1.00) | SLC6A4SLC6A2CACNA2D1 | |
| SCHEMBL20292538 | 0.87 | CACNA2D1 (1.00) | SLC6A4SLC6A2CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2089375-B1 | A METHOD OF PURIFICATION OF (S)-N-METHYL-3-(1-NAPHTYLOXY)-3-(2-THIENYL) PROPYLAMINE HYDROCHLORIDE (DULOXETINE) | ZENTIVA KS (CZ) | 2013-07-31 | — | — | EP | disclosed |
| US-8362279-B2 | Process for pure duloxetine hydrochloride | MSN LABORATORIES LIMITED (IN) | 2013-01-29 | — | — | US | disclosed |
| US-20100069649-A1 | METHOD OF PURIFICATION OF (S)-N-METHYL-3-(1-NAPHTYLOXY)-3-(2-THIENYL) PROPYLAMINE HYDROCHLORIDE (DULOXETINE) | ZENTIVA K.S. (CZ) | 2010-03-18 | — | — | US | disclosed |
| US-20090012315-A1 | Process for Pure Duloxetine Hydrochloride | MSN LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
| US-20080207923-A1 | Pure DNT-maleate and methods of preparation thereof | TEVA PHARMACEUTICALS USA, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207923-A1 | Pure DNT-maleate and methods of preparation thereof | TEVA PHARMACEUTICALS USA, INC. | 2008-08-28 | — | — | US | disclosed |
| WO-2007143065-A2 | PROCESS FOR PREPARING DULOXETINE AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-12-13 | — | — | WO | disclosed |
| US-20070281989-A1 | Process for preparing duloxetine and intermediates thereof | TEVA PHARMACEUTICALS USA, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281989-A1 | Process for preparing duloxetine and intermediates thereof | TEVA PHARMACEUTICALS USA, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20050197503-A1 | Process for the preparation of N-alkyl-N-methyl-3-hydroxy-3-(2-thienyl)-propylamines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207923-A1 | Pure DNT-maleate and methods of preparation thereof | DNTT, NCDN, AANAT | SLC6A4 6/4885SLC6A2 24/4885CACNA2D1 396/4885 |
| US-20070281989-A1 | Process for preparing duloxetine and intermediates thereof | UGT1A4, CYP3A4, CYP4B1 | SLC6A4 60/4885SLC6A2 105/4885CACNA2D1 3047/4885 |
| US-20100069649-A1 | METHOD OF PURIFICATION OF (S)-N-METHYL-3-(1-NAPHTYLOXY)-3-(2-THIENYL) PROPYLAMINE HYDROCHLORIDE (DULOXETINE) | PNMT, SLC6A2, HTR7 | SLC6A4 4/4885SLC6A2 2/4885CACNA2D1 507/4885 |
| US-20050197503-A1 | Process for the preparation of N-alkyl-N-methyl-3-hydroxy-3-(2-thienyl)-propylamines | HNMT, PNMT, HRH4 | SLC6A4 139/4885SLC6A2 465/4885CACNA2D1 2742/4885 |
| US-20090012315-A1 | Process for Pure Duloxetine Hydrochloride | OPRK1, OPRM1, OPRD1 | SLC6A4 5/4885SLC6A2 6/4885CACNA2D1 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.